Inspire Investing’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Inspire Investing’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,271	Closed	-$1.7M	–	1298
2026 Q1	$1.7M	Buy	+35,271	New	+$1.56M	0.1%	235

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Inspire Investing's KNSA Position: Q2 2026 in Review

Inspire Investing sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 35,271 shares — an estimated $1.7M sold.

Inspire Investing first reported a position in KNSA in Q1 2026 and held it in 1 quarter. The position peaked at $1.7M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Inspire Investing reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Inspire Investing sold 35,271 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.7M.
Inspire Investing first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Inspire Investing's Kiniksa Pharmaceuticals position peaked at $1.7M in Q1 2026.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.